Growth Metrics

Ligand Pharmaceuticals (LGNYZ) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Ligand Pharmaceuticals (LGNYZ) over the last 15 years, with Q3 2025 value amounting to $117.3 million.

  • Ligand Pharmaceuticals' Income towards Parent Company changed N/A to $117.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year change of. This contributed to the annual value of -$4.0 million for FY2024, which is 14216.22% down from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Income towards Parent Company of $117.3 million as of Q3 2025.
  • Ligand Pharmaceuticals' Income towards Parent Company's 5-year high stood at $117.3 million during Q3 2025, with a 5-year trough of -$42.5 million in Q1 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' median Income towards Parent Company value was -$4.7 million (recorded in 2021), while the average stood at -$33923.1.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Income towards Parent Company soared by 8068.87% in 2021, and later tumbled by 13603.29% in 2022.
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Income towards Parent Company stood at -$2.2 million in 2021, then tumbled by 32.75% to -$3.0 million in 2022, then skyrocketed by 43.58% to -$1.7 million in 2023, then crashed by 1767.15% to -$31.1 million in 2024, then surged by 477.23% to $117.3 million in 2025.
  • Its Income towards Parent Company was $117.3 million in Q3 2025, compared to $4.8 million in Q2 2025 and -$42.5 million in Q1 2025.